USPTO serial 88000887
PROFERO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MICKLEBURGH, LINDA BOHANNON
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PROFERO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical test kits for genetic testing for laboratory or research use; Assays and reagents for use in genetic research; Diagnostic preparations for scientific or research use; Nucleic acid isolation and purification kit consisting primarily of reagents for scientific research purposes; Reagents for scientific or medical research use; Clinical diagnostic preparations for clinical or medical laboratory use | ACTIVE | — |
| 005 | Testing kits comprised of medical diagnostic reagents and assays that test for the presence of certain genetic properties; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for the analysis of genetic material; Preparations for detecting changes in genes and gene expressions for medical purposes; Chemical reagents for medical analysis; Chemical preparation for use in medical analysis, particularly DNA analysis; Pharmaceutical preparations for diagnosis and for identifying and characterizing genetic abnormalities, tracking the progress of disease and measuring the effectiveness of therapies; Genetic identity tests comprises of reagents for medical purposes; Clinical diagnostic preparations for medical use | ACTIVE | — |
| 042 | Laboratory diagnostic services in the field of molecular science, comparative genome analysis, nucleic acid arrays and screening of nucleic acids; Medical and scientific research in the field of genetic testing and diagnosis and treatment of medical conditions; Development of tests and laboratory testing in the field of genetics and human disease; Scientific research consulting in the field of genetics, genomics, nucleic acid sequencing, and bioinformatics; Consulting services in the field of pharmaceutical research and development and laboratory testing; Genetic research, development and testing services; Genomic research, development and testing services for scientific research purposes; Nucleic acid collection, testing and analysis services for scientific research purposes; Genetic testing for scientific diagnostic research purposes; Genomic testing for scientific diagnostic research purposes; Medical and scientific research, development and consulting in the field of neurology; Medical and scientific research in the field of genetics and genetic engineering; Medical and scientific research and consulting in the fields of genomics and generation sequencing; Medical and scientific research in the field of disease treatment and diagnosis; Medical and scientific research relating to the design and development of treatment therapies; Data collection for research purposes, namely, the collection, testing and research of patient molecular and/or genomic data; Scientific clinical studies, namely, conducting clinical trials for others; Retrieval and correlation of genomic data for research or analysis purposes; Conducting clinical and pre-clinical trials; Targeted pharmaceutical drug development services; Genotyping services for research or analysis purposes; Gene screening for research or analysis purposes; Gene isolation and gene expression analysis for scientific and medical research purposes; Gene mapping; Gene analysis and biomarker discovery for scientific research and medical purposes; Research and development of identification and treatment methods for hereditary factors leading to disease; Nucleic acid-sequencing for scientific research purposes | ACTIVE | — |
| 044 | Medical diagnostic services in the field of molecular science, comparative genome analysis, nucleic acid arrays and screening of nucleic acids; Medical testing, analysis, and evaluation services for medical or diagnostic purposes for providing healthcare information; Providing health care information featuring information resulting from genomic research, testing, analysis, and evaluation; Diagnosis and treatment of medical conditions, namely, of cognitive, neurological, and brain-related conditions; Providing healthcare information; Providing information in the field of disease prevention, screening, diagnosis, and treatment for medical diagnostic and treatment purposes; Medical testing services for diagnostic or treatment purposes in the medical field; Proteogenomic profiling for diagnostic or treatment purposes of cognitive, neurological, and brain-related conditions; Identification of target molecules for disease treatment, namely, treatments of cognitive, neurological, and brain-related conditions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by The Translational Genomics Research Institute
- Other trademarks owned by The Translational Genomics Research Institute
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PROFERO
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 15, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 15, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 13, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 12, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jan 12, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 5, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jan 5, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 6, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 2, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 2, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 2, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 24, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 22, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 22, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 22, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 3, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 1, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 1, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 1, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 18, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 16, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 16, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 16, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 9, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 14, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 1, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2019 | ALIE | ASSIGNED TO LIE | — |
| Mar 8, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 4, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 18, 2018 | NWAP | NEW APPLICATION ENTERED | — |